Skip to NavigationSkip to content

Dr Laurent Audoly joins Pieris

Published on: 09/06/10

French biotech company Pieris has appointed Dr Laurent Audoly as chief scientific officer.

Dr Audoly was most recently biologics research site lead at Merck & Co, and has both pharma and biotech experience, with extensive expertise in therapeutic protein drug development.

"As a keen proponent of targeted therapeutic technologies, I am excited to join Pieris at a stage where the Anticalin approach is beginning to demonstrate its great therapeutic potential," he said. "My goal is to combine my experience from big pharma and biotech with the capabilities present at Pieris to bring the full spectrum of R&D operations to the next level."

Dr Audoly has held research and managerial positions of increasing responsibility, first as senior research scientist in the department of inflammation at Pfizer and then as senior research fellow in the department of pharmacology at Merck & Co.

Following his first stint at Merck Laurent joined MedImmune as director of inflammation R&D before returning to Merck as biologics research site lead.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches